Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Apalutamide (Johnson & Johnson) Drug Analysis 2018: An Orally Available Androgen Signaling Inhibitor -

Research and Markets
Posted on: 15 Feb 18

The "Drug Analysis: Apalutamide" drug pipelines has been added to's offering.

Apalutamide (Johnson & Johnson) is an orally available androgen signaling inhibitor. The drug exhibits high binding affinity to the ligand-binding domain of androgen receptor (AR) and subsequently inhibits its nuclear import, as well as its ability to bind to DNA. Apalutamide has a similar mechanism of action to Xtandi (enzalutamide; Pfizer/Astellas).

However, in preclinical development, apalutamide exhibited reduced binding to plasma proteins, which resulted in increased efficacy at lower exposure rates than those required for Xtandi. Brain-levels (the concentration of the drug in brain tissue) were lower for apalutamide than for Xtandi, which could indicate a lower seizure-induction risk with apalutamide.

Apalutamide is poised to become the next AR inhibitor to reach the market following the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) in non-metastatic castration-resistant prostate cancer (nmCRPC) patients. The submission to the FDA was based on the Phase III SPARTAN trial, which met its primary endpoint of metastasis-free survival (MFS).

Approval in this population would expand Johnson & Johnson's prostate cancer treatment portfolio and pair an AR inhibitor with its blockbuster 17 alpha-hydroxylase (CYP17) inhibitor Zytiga (abiraterone acetate). However, if approved, apalutamide may face direct competition from the established AR inhibitor Xtandi, which also improved MFS in nmCRPC patients in the Phase III PROSPER study.

Key Topics Covered:

List of Figures

Figure 1: Apalutamide for prostate cancer - SWOT analysis

Figure 2: Drug assessment summary of apalutamide for prostate cancer

Figure 3: Drug assessment summary of apalutamide for prostate cancer

Figure 4: Apalutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Apalutamide drug profile

Table 2: Apalutamide Phase III data in prostate cancer

Table 3: Apalutamide Phase I/II data in prostate cancer

Table 4: Apalutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 15/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.